Navigation Links
First step to new therapy for chronic bowel disease
Date:7/6/2010

Scientists associated with VIB (Flanders Institute for Biotechnology) and Ghent University (UGent) have discovered that A20 protein plays an important protective role in diseases associated with chronic bowel inflammation. This makes A20 into a promising therapeutic target for the development of new anti-inflammatory drugs.

Chronic bowel inflammation

Inflammation is a normal protective reaction against tissue damage and infection. This immune response is very specific and only possible after a whole cascade of signals. Sometimes, however, something goes awry in the chain of reactions, leading to an out-of-control inflammation process and possibly undesirable responses against endogenous substances. Crohn's disease and ulcerative colitis are both chronic inflammatory disorders of the gastrointestinal tract. Hence, reining in the runaway immune system would seem to be the obvious treatment for these diseases. But this requires a thorough knowledge of the whole process.

TNF, NF-κB and A20

The NF-κB protein plays a critical role in the inflammatory response and is activated by e.g. TNF, which is produced by the white blood cells and acts as a kind of messenger molecule between multiple cell types. This leads in the cell to the production of e.g. A20, a protein that shuts down NF-κB activation and is able to prevent cell death.

A20, new therapeutic target

To identify the physiological role of A20 protein, Lars Vereecke and his colleagues, under the leadership of Geert van Loo and Rudi Beyaert, studied mice whose intestinal epithelial cells (cells that line the intestinal wall) were incapable of producing A20 protein. Their experiments showed that the intestinal epithelial cells of these mice were very sensitive to TNF-induced apoptosis, which in turn made them highly susceptible to developing chronic bowel inflammation. When intestinal epithelium breaks down, bacteria have a chance to penetrate the intestinal tissue, which will trigger a systemic inflammatory response.

In a normal or healthy environment, the role of A20 protein is quite limited. It mainly plays a protective role in the presence of intestinal damage or inflammation. This study confirms the results of a genome-wide analysis, involving a large number of patients, which showed that defects in A20 can play a role in the development of Crohn's disease. This makes A20 protein a promising target for the development of new drugs to treat chronic inflammatory bowel disease.


'/>"/>

Contact: Joris Gansemans
joris.gansemans@vib.be
329-244-6611
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology technology :

1. IIVS Receives First Mark Twain Ethical Science Award for Successes In Replacing Animals for Chemical and Product Safety Testing
2. Sandia Labs reports first monolithic terahertz solid-state transceiver
3. FDA Approves First-of-Its-Kind HIV Test Which Can Detect HIV Days Earlier Than Current U.S. Tests
4. Texas A&M veterinary researchers achieve cloning first
5. First DePuy ASR Hip Replacement Lawsuit Filed in the US
6. Huiheng Medical, Inc. Announces Conference Call to Discuss First Quarter 2010 Results
7. FirstAidWarehouse.co.uk Examines High Blood Pressure, or Hypertension, and Blood Pressure Monitors
8. YM BioSciences enrolls first US patient in Phase II randomized, double-blind brain metastases trial for nimotuzumab
9. Concord Medical Announces First Quarter 2010 Financial Results
10. t2cure First Company to Have Quality of Cellular Therapeutic Certified by EMA
11. Launch of GenoCon: First-ever Contest in Rational Genome Design Based on Semantic-web Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... ... 29, 2016 , ... During a two day program for ... company, CereScan’s CEO, John Kelley, joined other Denver business leaders in providing business ... the Denver area business community, shared his top fundamental learnings in building an ...
(Date:4/29/2016)... Italy , April 29, 2016 ... 5.11, the latest update to its industry-leading treatment planning ... shown that Monaco version 5.11 ... can now attain calculation speeds up to four times ... . With the industry,s gold standard ...
(Date:4/28/2016)... ... 28, 2016 , ... Connecticut Innovations (CI), the ... announced the launch of VentureClash , a $5 million global investment challenge ... looks to attract the best early-stage companies here in Connecticut, around the country ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... an open house for regional manufacturers at its Maple Grove, Minnesota technical center, ... Hardinge Group, Chiron and Trumpf. Almost 20 leading suppliers of tooling, accessories, ...
Breaking Biology Technology:
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... has announced the addition of the  "Global ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... sector to grow at a CAGR of ... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ) has announced the addition ...
(Date:3/1/2016)... March 1, 2016 ... addition of the  "Global Biometric Access ... to their offering. --> ... of the  "Global Biometric Access Control ... their offering. --> Research ...
(Date:3/1/2016)... SAN FRANCISCO , March 1, 2016 ... and BitGo, Inc. extends biometric authentication to the blockchain ... keys. Bitcoin transactions that have ... month in digital assets with over 10,000 transactions on ... startup. HYPR enables enterprises to keep encrypted biometric data ...
Breaking Biology News(10 mins):